Overall survival · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neurotoxicity · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel probably leads to lower neurotoxicity compared with 250 mg/m2 paclitaxel (moderate certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in overall survival compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in response rate compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neurotoxicity · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in neurotoxicity compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Alopecia ‐ not measured · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found